The newly formed company will focus on developing therapeutics for neurodegenerative diseases. Credit: Raman Oza / Pixabay.
Aprinoia Therapeutics and Ross Acquisition have entered a definitive agreement for a business combination.
Under the agreement, both companies will form a combined entity, dubbed Aprinoia Therapeutics, with an enterprise value of up to $319.6m.
Ross Acquisition and Aprinoia Therapeutics will each become a wholly owned subsidiary of the newly formed company, focusing on neurodegenerative diseases.
As part of the deal, Ross made an investment of $7.5m in the combined entity through a convertible note and is committed to providing a capital infusion of up to…